Abcellera Biologics is trading 4.15% up now at $10.16, extending a sharp multi-session rally after positive Phase 2 results for ABCL635, its investigational menopause treatment.
- The company announced a proposed $200 million underwritten offering of common shares and pre-funded warrants.
- Proceeds would fund ABCL635 development, pipeline research, and working capital; the offering introduces potential dilution, but the clinical update remains the stronger bullish catalyst.